Niguarda, among the largest Italian hospitals, is a national and international reference center for many therapeutic areas. It hosts all clinical specialties for adult and pediatric pathologies. At the forefront of research and trials on new therapies in collaboration with international structures. It will be Level II Spoke.

The Laboratory of Advanced Cellular Therapies is part of Hematology of AULSS8 Berica and is currently the only public facility authorized in the Triveneto area for the production of cell therapies, in particular for mesenchymal stromal cells (MSCs) and CIK cells. The Hematology Unit is authorized for clinical use of commercial CAR-T therapies.

Private non-profit organization operating in the biomedical research sector, in particular in the area of ​​childhood leukemia. It represents the first example in Italy of a research structure in the field of childhood leukemia that operates in an integrated manner with an Healthcare center. It will be Spoke Level 2 within the project.

As IRCCS in the disciplines of "assistance and research in transplants and critically ill patients" and "integrated medical and surgical management of oncological pathologies", it represents an institution of national importance with research purposes, mainly clinical and translational, in the biomedical field. It will be an affiliate of the project.

The European Institute of Oncology, IRCCS, is a comprehensive cancer center that aims to achieve excellence in the prevention, diagnosis and treatment of cancer through the development of clinical-translational research and organisational innovation, in a context of constant attention to the quality of the service provided to patients.

IRST-IRCCS has consolidated experience in the production of ATMPs and the treatment of patients with cellular products. There are currently several active clinical trials in solid tumors. The infrastructure consists of two clean rooms, with the possibility of having two separate production lines.

The University of Pisa is one of the most renowned educational institutions in Italy. Famous alumni of the University include Galileo Galilei and Nobel Prize winners such as Giosuè Carducci, Enrico Fermi and Carlo Rubbia. Nowadays UNIPI represents a prestigious modern centre for teaching and advanced research, covering all disciplinary areas.

Perugia Hospital, in agreement with the University, constitutes a highly specialized healthcare center which, due to the specific professionalism present, the complex of innovative technologies and type of services offered, is a point of excellence both for Umbrian healthcare than for the national one.

The S. Maria di Terni Hospital is a highly specialized healthcare centre. It is committed to driving innovation through cutting-edge technologies in diagnosis, treatment and translational research. It stands out for its pioneering role in cell therapies since 2010. It will be a second level spoke in the project.

IDI-IRCCS is a landmark in Italy and Europe in the field of skin pathologies offering high-quality healthcare services based on an integrated multidisciplinary approach for each skin pathology. IDI-IRCCS is also a regional and ERN-SKIN Reference Center for the diagnosis and treatment of rare dermatological diseases.

The Foundation is a not-for-profit institution. It pursues the aim of protecting and promoting the human person in the field of healthcare, training, scientific, research and innovation in the biomedical and health fields, both clinical and translational.

National reference hospital and pediatric center for the Campania region and southern Italy in pediatric emergency and high specialty care. It will collaborate as a second-level Spoke with other LSH-TA project partners to facilitate the production and introduction of ATMP medicinal products into clinical practice.

UNICH scientists have strong scientific experience on several and relevant scientific topics likewise haematology, as well as on the study of T cells and extracellular vesicles. The scientist team conducts synergistic activities, cooperating with several core facilities (genomic, proteomic, flow cytometry) within the same institution with the aim to translate the therapies based on T regulatory cells and their derived extracellular vesicles, as well as pathogen specific T cells to the clinical practice.

CNR-NANOTEC develops fundamental and applied research in the field of nanotechnology. It gathers scientists from the disciplines of physics, chemistry, materials science, biology and medicine for developing cutting-edge nanotechnology-based solutions in close collaboration with academic, institutional and industrial partners.

Federico II University of Naples is one of the most prestigious academic institutions in Italy, with a long history of excellence in research and education. Established in 1224 by Frederick II of Hohenstaufen, it is one of the oldest universities in the world and continues to uphold a high standard of education and research. The University Hospital is one of the main hospital facilities affiliated with Federico II. Located in the heart of Naples, it plays a crucial role in the training of medical and surgical students through practical internships and clinical training programs. It is also a center of excellence for medical research, where advanced studies are conducted on a wide range of diseases and treatments. The Department of Medicine and Surgery at Federico II is one of the most renowned in Italy and offers a wide range of undergraduate, master's, and doctoral programs in medicine, surgery, and related disciplines. Its faculty and researchers are leaders in their fields and contribute significantly to medical knowledge through innovative research and advanced clinical practice. It is a clinical center in Southern Italy authorized for the infusion of CAR T cells.